Table 2

Combined estimates and sensitivity analyses for each of the groups

Cancer and drugStudiesCombined risk estimate (95% CI)
Esophageal cancer and all bisphosphonates—main analysisVestergaard-DNR, Vinogradova-CPRD, Vinogradova-QRes, Chiang-NHICD, Nguyen-VAD1.11 (0.97 to 1.27)
 Sensitivity analysis (1)Vestergaard-DNR, Wright-CPRD, Vinogradova-QRes, Chiang-NHICD, Nguyen-VAD1.29 (0.97 to 1.72)
 Sensitivity analysis (2)Vestergaard-DNR, Green-CPRD, Vinogradova-QRes, Chen-NHICD, Nguyen-VAD1.11 (0.95 to 1.29)
 Sensitivity analysis (3)Vestergaard-DNR, Cardwell-CPRD, Vinogradova-QRes, Lee-NHICD, Nguyen-VAD1.03 (0.88 to 1.22)
Gastric cancer and all bisphosphonatesVestergaard-DNR, Vinogradova-CPRD, Vinogradova-QRes, Chiang-NHICD0.96 (0.82 to 1.12)
Esophageal cancer and alendronate—main analysisAbrahamsen-DNR, Vinogradova-CPRD, Vinogradova-QRes, Chiang-NHICD, Nguyen-VAD0.98 (0.87 to 1.11)
 Sensitivity analysis (1)Abrahamsen-DNR, Wright-CPRD, Vinogradova-QRes, Chen-NHICD, Nguyen-VAD0.97 (0.70 to 1.34)
 Sensitivity analysis (2)Abrahamsen-DNR, Cardwell-CPRD, Vinogradova-QRes, Chen-NHICD, Nguyen-VAD0.85 (0.71 to 1.02)
 Sensitivity analysis (3)Abrahamsen-DNR, Cardwell-CPRD, Vinogradova-QRes, Lee-NHICD, Nguyen-VAD0.86 (0.72 to 1.04)
Gastric cancer and alendronateAbrahamsen-DNR, Chiang-NHICD, Vinogradova-QRes, Vinogradova-CPRD0.99 (0.71 to 1.38)
Upper GI cancer and all bisphosphonatesCohort studies: Vestergaard-DNR, Cardwell-CPRD, Chiang-NHICD1.32 (0.81 to 2.13)
Upper GI cancer and all bisphosphonatesCase control studies: Vinogradova-CPRD, Vinogradova-QRes, Nguyen-VAD, Chen-NHICD1.06 (0.93 to 1.22)
  • CPRD, Clinical Practice Research Data Link Database; DNR, Danish National Registries; GI, gastrointestinal; NHICD, National Health Insurance Claims Database; Qres, Q-Research; VAD, Veterans Affairs Database.